Inovio completes enrollment of phase 1b clinical trial for its dna vaccine candidate against lassa fever, ino-4500, in west africa

Plymouth meeting, pa., oct. 26, 2021 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced its phase 1b clinical trial for ino-4500, its dna vaccine candidate for lassa fever, completed full enrollment of 220 participants.
INO Ratings Summary
INO Quant Ranking